Slow Capital Inc. bought a new stake in shares of Nektar Therapeutics (NASDAQ:NKTR) during the 4th quarter, Holdings Channel reports. The firm bought 15,381 shares of the biopharmaceutical company’s stock, valued at approximately $919,000.

Other institutional investors have also made changes to their positions in the company. BB&T Investment Services Inc. bought a new stake in Nektar Therapeutics during the 4th quarter valued at $119,000. Meeder Asset Management Inc. bought a new stake in shares of Nektar Therapeutics in the 4th quarter worth $121,000. SeaCrest Wealth Management LLC bought a new stake in shares of Nektar Therapeutics in the 4th quarter worth $200,000. Kovack Advisors Inc. bought a new stake in shares of Nektar Therapeutics in the 4th quarter worth $240,000. Finally, Sicart Associates LLC bought a new stake in shares of Nektar Therapeutics in the 4th quarter worth $245,000. 96.21% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

In other Nektar Therapeutics news, Director Christopher A. Kuebler sold 30,000 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $58.66, for a total value of $1,759,800.00. Following the completion of the sale, the director now owns 70,500 shares of the company’s stock, valued at $4,135,530. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, COO John Nicholson sold 220,144 shares of the business’s stock in a transaction dated Wednesday, March 7th. The stock was sold at an average price of $99.27, for a total value of $21,853,694.88. Following the completion of the sale, the chief operating officer now directly owns 267,657 shares of the company’s stock, valued at approximately $26,570,310.39. The disclosure for this sale can be found here. Insiders have sold 399,592 shares of company stock worth $36,001,781 in the last quarter. 5.44% of the stock is currently owned by corporate insiders.

NKTR has been the topic of a number of research reports. Zacks Investment Research downgraded Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Canaccord Genuity reissued a “buy” rating and issued a $80.00 price objective (up previously from $50.00) on shares of Nektar Therapeutics in a research note on Wednesday, January 10th. Jefferies Group boosted their price objective on Nektar Therapeutics from $2.12 to $88.00 and gave the stock a “buy” rating in a research note on Tuesday, January 16th. Mizuho boosted their price objective on Nektar Therapeutics from $45.00 to $89.00 and gave the stock a “buy” rating in a research note on Monday, January 22nd. Finally, BidaskClub downgraded Nektar Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 8th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $54.75.

Nektar Therapeutics stock opened at $106.91 on Thursday. The company has a quick ratio of 5.63, a current ratio of 5.82 and a debt-to-equity ratio of 2.79. The stock has a market capitalization of $17,250.93, a price-to-earnings ratio of -164.48 and a beta of 1.96. Nektar Therapeutics has a 1-year low of $17.33 and a 1-year high of $111.36.

Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.14. The business had revenue of $95.47 million for the quarter, compared to analysts’ expectations of $36.96 million. Nektar Therapeutics had a negative return on equity of 156.85% and a negative net margin of 31.42%. The company’s quarterly revenue was up 154.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.28) EPS. analysts anticipate that Nektar Therapeutics will post -1.33 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Slow Capital Inc. Takes $919,000 Position in Nektar Therapeutics (NKTR)” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/slow-capital-inc-takes-919000-position-in-nektar-therapeutics-nktr/1957694.html.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.